

SEQUENCE LISTING

<110> APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

<120> Amylin aggregation inhibitors and use thereof.

<130> WO/817

<160> 17

<170> PatentIn version 3.1

<210> 1

<211> 7

<212> PRT

<213> synthetic construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa, if present, can be Aspartic acid or derivative thereof selected from acylated and alkylated Aspartic Acid;

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa is Leucine or when Xaa in position 7 is absent, Xaa is selected from Leucine and amidated Leucine

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa can be absent or is selected from Aspartic Acid and amidated Aspartic Acid

<400> 1

Xaa Phe Gly Ala Pro Xaa Xaa
1 5

<210> 2

<211> 6

<212> PRT

<213> synthetic construct

<400> 2

Asp Phe Gly Ala Pro Leu
1 5

<210> 3

<211> 6

<212> PRT

<213> synthetic construct

<220>

<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is acetylated aspartic acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is amidated Leucine

<400> 3

Xaa Phe Gly Ala Pro Xaa
1 5

<210> 4
<211> 7
<212> PRT
<213> synthetic construct

<400> 4

Asp Phe Gly Ala Pro Leu Asp
1 5

<210> 5
<211> 37
<212> PRT
<213> human

<400> 5

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 6
<211> 37
<212> PRT
<213> Cat

<400> 6

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Ile Arg Ser Ser Asn Asn Leu Gly Ala Ile Leu Ser Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 7
<211> 37
<212> PRT
<213> Hamster

<400> 7

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val His Ser Ser Asn Asn Leu Gly Pro Val Leu Ser Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 8
<211> 37
<212> PRT
<213> Rat

<400> 8

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 9
<211> 37
<212> PRT
<213> Mouse

<400> 9

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 10
<211> 7
<212> PRT
<213> human

<400> 10

Asn Phe Gly Ala Ile Leu Ser
1 5

<210> 11
<211> 7
<212> PRT
<213> synthetic constuct

<400> 11

Asn Phe Gly Ala Pro Leu Ser
1 5

<210> 12
<211> 7
<212> PRT
<213> synthetic construct

<400> 12

Asp Phe Gly Ala Ile Leu Asp
1 5

<210> 13
<211> 7
<212> PRT
<213> synthetic construt

<400> 13

Asp Pro Gly Ala Ile Leu Asp
1 5

<210> 14
<211> 7
<212> PRT
<213> synthetic construct

<400> 14

Asp Phe Pro Ala Ile Leu Asp
1 5

<210> 15
<211> 7
<212> PRT
<213> synthetic construct

<400> 15

Asp Phe Gly Pro Ile Leu Asp
1 5

<210> 16

<211> 7

<212> PRT

<213> synthetic construct

<400> 16

Asp Phe Gly Ala Ile Pro Asp
1 5

<210> 17

<211> 6

<212> PRT

<213> synthetic construct

<400> 17

Phe Gly Ala Pro Leu Asp
1 5